Ripening of the cervix with prostaglandin E2-gel. A randomized study with a new ready-to-use compound of triacetin-prostaglandin-E2-gel.
A randomized study with a group of patients treated with a new ready-to-use triacetin-prostaglandin E2-gel compared to a non-treated group was conducted. The gel-treated group showed a distinct difference in cervical score after 12 h and ten patients were delivered during this period without further induction attempt compared to none in the control group. There was a significantly lower need for oxytocin stimulation in the treated group (P less than 0.0005), but there was no difference in the cesarean section rate or instrumental delivery rate. No side-effects were seen. This new gel seems effective and safe.
D000328:Adult; D002584:Cervix Uteri / Q000187:drug effects*; D004106:Dilatation; D015232:Dinoprostone; D005260:Female; D005782:Gels; D006801:Humans; D011247:Pregnancy / Q000187:drug effects*; D011458:Prostaglandins E / Q000008:administration & dosage / Q000494:pharmacology*; D011897:Random Allocation; D014215:Triacetin / Q000008:administration & dosage / Q000494:pharmacology*; D014280:Triglycerides / Q000494:pharmacology*; D014590:Uterine Contraction / Q000187:drug effects*
D005782:Gels; D011458:Prostaglandins E; D014280:Triglycerides; D015232:Dinoprostone; D014215:Triacetin